Eventide Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
Other funds holding MDGL
BBA
Eventide Asset Management's MDGL Position: Q3 2026 in Review
Eventide Asset Management increased its Madrigal Pharmaceuticals (MDGL) stake by 59% in Q3 2026, buying an estimated $164K and bringing the position to 836 shares worth $426K. The position accounts for 0.01% of the portfolio, ranked #267.
Eventide Asset Management first reported a position in MDGL in Q1 2018 and has held it in 5 quarters since. The position peaked at $12.9M in Q2 2018. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.
- Eventide Asset Management held 836 shares of Madrigal Pharmaceuticals worth $426K as of Q3 2026.
- Eventide Asset Management bought 310 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $164K.
- Madrigal Pharmaceuticals made up 0.01% of Eventide Asset Management's portfolio in Q3 2026, its #267 holding.
- Eventide Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2018 and has held it in 5 quarters since.
- Eventide Asset Management's Madrigal Pharmaceuticals position peaked at $12.9M in Q2 2018.
- 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.
Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.